Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
The Lancet. Haematology|May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 studyPierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
Blood Advances|October 17, 2024
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemiaRomane Joudinaud, Augustin Boudry, Laurène Fenwarth, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
American Journal of Hematology|December 23, 2015
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment studyMichael Loschi, Raphael Porcher, Fiorenza Barraco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
Pageof 7